# A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

Source: https://onco.cc/trials/nct05944978/  
OnCo record `nct05944978` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GNC-035 in chronic lymphocytic leukaemia, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies is a phase 1/2 interventional study registered as NCT05944978 by Sichuan Baili Pharmaceutical Co., Ltd., with 3 participants enrolled, started 2023-08-16 and due to reach its primary completion in 2025-12. Interventions recorded: GNC-035.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05944978
- Phase: 1/2
- Setting: Phase Ib/II Clinical Study of GNC-035 Tetra-specific Antibody Injection in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 3

## Sources

- ClinicalTrials.gov NCT05944978: https://clinicaltrials.gov/study/NCT05944978

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct05944978.json